发布求助
文献互助 智能选刊 最新文献

THERAPEUTISCHE UMSCHAU最新文献

筛选
英文 中文
[Medical reporting obligations and reporting rights]. [医疗报告义务和报告权利]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-10-01 DOI: 10.23785/TU.2024.06.005
Esther Schaffner
{"title":"[Medical reporting obligations and reporting rights].","authors":"Esther Schaffner","doi":"10.23785/TU.2024.06.005","DOIUrl":"10.23785/TU.2024.06.005","url":null,"abstract":"<p><strong>Introduction: </strong>Medical confidentiality protects the patient's privacy and medical data with criminal consequences in the event of a breach. It continues to exist even after the end of professional practice. Exceptions apply with the patient's consent or official authorisation. This paper describes various reporting obligations, e.g. in the case of exceptional deaths, abortions, communicable diseases and significant injuries caused by dogs. There are also reporting rights, e.g. for children or adults who are at risk. Some reports must be made anonymously, others require full patient details to be provided. Violations of the reporting obligations are punishable by law.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 6","pages":"207-213"},"PeriodicalIF":0.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Medicine and Law: an Introduction - Part 1]. [医学与法律：导论-第一部分]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-10-01 DOI: 10.23785/TU.2024.06.001
Thomas D Szucs
{"title":"[Medicine and Law: an Introduction - Part 1].","authors":"Thomas D Szucs","doi":"10.23785/TU.2024.06.001","DOIUrl":"https://doi.org/10.23785/TU.2024.06.001","url":null,"abstract":"<p><strong>Introduction: </strong>The development of Swiss medical law is closely linked to social and medical development. In the early days and in the Middle Ages, healers and monasteries shaped medical care, with canon law playing an important role. In the early modern period, the first regional regulations for the medical profession emerged. With the founding of the federal state in 1848, the modernisation of medical law began; important laws such as the Factory Act (1877) and the first Health Insurance Act (1911) were introduced. In the 20th century, the introduction of the AHV/IV (1948) and the Health Insurance Act (KVG, 1996) marked the beginning of further professionalisation. Medical law is currently being adapted to meet modern ethical and legal challenges through laws such as the Human Research Act (2014) and remains a dynamic field.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 6","pages":"180-187"},"PeriodicalIF":0.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gout and Nutrition]. [痛风与营养]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.005
Barbara Ankli
{"title":"[Gout and Nutrition].","authors":"Barbara Ankli","doi":"10.23785/TU.2024.05.005","DOIUrl":"https://doi.org/10.23785/TU.2024.05.005","url":null,"abstract":"<p><strong>Introduction: </strong>Gout, the most common arthritis worldwide, is closely linked to cardiovascular disease and metabolic syndrome. The most impor-tant risk factor for developing gout is hyperuricemia. Serum uric acid is the end product of purine metabolism and can be partially influenced by dietary changes. Since a quarter of serum uric acid is excreted via the intestine, there is also a connection with diet here - keyword microbiome. Recently, genetic predispositions and drug therapy for gout have come to the fore. However, since cardiovascular comorbidities exist in high frequency, a dietary adjustment also makes sense to improve the comorbidities. Recently, the focus has shifted away from simply reducing purine intake in favor of introducing a largely plant-based diet. Reducing alcohol consumption makes sense for many reasons but does not lead to a significant reduction in serum uric acid. In addition to drug therapy, however, all possibilities should be exploited to enable a rapid reduction in serum uric acid to the target range; a change in diet can contribute to this. A change in diet can also have a positive effect on the frequency of gout flares. Targeted, structured information for patients promotes their knowledge of the disease and motivation to achieve their serum uric acid (SUA) goal. The right diet may be the personal contribution to quickly reaching the SUA target level and freedom from gout flares.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"164-167"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Therapy of gout in 2024]. [2024 年痛风治疗]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.004
Adrian Forster
{"title":"[Therapy of gout in 2024].","authors":"Adrian Forster","doi":"10.23785/TU.2024.05.004","DOIUrl":"https://doi.org/10.23785/TU.2024.05.004","url":null,"abstract":"<p><strong>Introduction: </strong>The treatment of gout includes anti-inflammatory therapy and prophylaxis of flare-ups on the one hand and measures for long-term uric acid reduction on the other. Acute arthritis urica is best relieved by intra-articular steroids; systemic steroids, NSAIDs and, in exceptional cases, colchicine are also suitable. For the prophylaxis of relapses, long-term use of colchicine, NSAIDs or low-dose steroids is an option. However, the main pillar of gout therapy is pharmacological reduction of uric acid. The xanthine oxidase inhibitors allopurinol and febuxostat are best suited. The goal is a serum uric acid below 360 µmol/l (\"treat to target\"). The «start low, go slow» strategy reduces the risk of relapses and, in the case of allopurinol, the occurrence of hypersensitivity syndrome. Allopurinol is started at a maximum of 100 mg/d (less in renal insufficiency), followed by a slow upward titration to the required maintenance dose, which may largely exceed 300 mg/d (also in renal insufficiency). Febuxostat is started at a maximum of 40 mg/d and also titrated upwards. The most common cause of insufficient uric acid reduction is unreliable medication intake. In the management of gout, its comorbidities should also be sought and addressed.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"160-163"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gicht im Wandel der Zeiten: von der Krankheit der Könige zur Hyperurikämie als Organ-Risikofaktor. 痛风的历史：从国王的疾病到作为器官风险因素的高尿酸血症。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.001
Marcel Weber
{"title":"Gicht im Wandel der Zeiten: von der Krankheit der Könige zur Hyperurikämie als Organ-Risikofaktor.","authors":"Marcel Weber","doi":"10.23785/TU.2024.05.001","DOIUrl":"10.23785/TU.2024.05.001","url":null,"abstract":"<p><strong>Introduction: </strong></p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"151-152"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Imaging in crystal arthropathies]. [晶体关节病的成像技术］
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.007
Florian Alexander Huber, Roman Guggenberger
{"title":"[Imaging in crystal arthropathies].","authors":"Florian Alexander Huber, Roman Guggenberger","doi":"10.23785/TU.2024.05.007","DOIUrl":"https://doi.org/10.23785/TU.2024.05.007","url":null,"abstract":"<p><strong>Introduction: </strong>Crystal arthropathies present a complex entity for radiological diagnostics, often reflecting rheumatologic and other diseases. Over the past decades, the evidence and applicability of various radiological techniques, with and without the use of ionizing radiation, have significantly evolved. This article provides an overview of the current evidence on the use of different modalities and their advantages and disadvantages for the diagnosis and therapy monitoring of crystal arthropathies, based on the latest guidelines from relevant professional societies. In addition to established methods such as X-ray, ultrasound and MRI, this work also addresses newer methods such as dual-energy computed tomography (CT) and photon-counting CT.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"172-178"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in treatment of hyperuricemia and gout. 高尿酸血症和痛风的治疗进展。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.006
Alexandre Dumusc, Alexander So
{"title":"Advances in treatment of hyperuricemia and gout.","authors":"Alexandre Dumusc, Alexander So","doi":"10.23785/TU.2024.05.006","DOIUrl":"https://doi.org/10.23785/TU.2024.05.006","url":null,"abstract":"<p><strong>Introduction: </strong>Gout is an inflammatory arthritis that is commonly associated with chronic diseases such as chronic kidney disease (CKD), hypertension, coronary vascular disease, and the metabolic syndrome. Therefore, the management of gout (treatment of the acute flare, lowering serum urate [sUA]) needs to take these co-morbid conditions in consideration. Recent advances in gout therapy showed the effectiveness of new and existing therapies in gout management and we will summarize those we consider to have the largest impact on our clinical practice in this article.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"168-171"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Calcium pyrophosphate deposition (CPPD) disease - more than just "pseudogout"]. [焦磷酸钙沉积症（CPPD）--不仅仅是 "假性痛风"]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.003
Tobias Manigold
{"title":"[Calcium pyrophosphate deposition (CPPD) disease - more than just \"pseudogout\"].","authors":"Tobias Manigold","doi":"10.23785/TU.2024.05.003","DOIUrl":"https://doi.org/10.23785/TU.2024.05.003","url":null,"abstract":"<p><strong>Introduction: </strong>Calcium pyrophosphate deposition (CPPD) disease plays an important - and sometimes underestimated - role in rheumatology practice. Clinically, CPP-arthritis is often indistinguishable from gout and is therefore commonly referred to as \"pseudogout\". In contrast to gout, CPPD cannot be cured but can only be treated symptomatically. The pathophysiology, diagnosis, therapy and new therapeutic approaches to CPPD are discussed below.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"156-159"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Gout - clinical presentation]. [痛风--临床表现]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-09-01 DOI: 10.23785/TU.2024.05.002
Andreas Krebs
{"title":"[Gout - clinical presentation].","authors":"Andreas Krebs","doi":"10.23785/TU.2024.05.002","DOIUrl":"https://doi.org/10.23785/TU.2024.05.002","url":null,"abstract":"<p><strong>Introduction: </strong>Gout is a common form of inflammation, characterized by sudden, severe attacks of pain, swelling, redness and tenderness. The diagnosis is based on the typical clinical pattern, but the definitive diagnosis requires the identification of urat crystals in the joint fluid or in ultrasound or DECT. The differential diagnosis includes always infection or other crystal arthropathies, in atypical presentation also other forms of arthritis, e.g. peripheral spondylarthritis.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 5","pages":"153-155"},"PeriodicalIF":0.2,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Dyspnea in patients in palliative situations - the invisible symptom]. [姑息治疗患者的呼吸困难--看不见的症状]。
IF 0.2
THERAPEUTISCHE UMSCHAU Pub Date : 2024-08-01 DOI: 10.23785/TU.2024.04.008
Sandra Eckstein
{"title":"[Dyspnea in patients in palliative situations - the invisible symptom].","authors":"Sandra Eckstein","doi":"10.23785/TU.2024.04.008","DOIUrl":"https://doi.org/10.23785/TU.2024.04.008","url":null,"abstract":"<p><strong>Introduction: </strong>Dyspnea is a common and distressing symptom in patients with advanced malignant and non-malignant diseases. It is a subjective experience that can only be described by the patients themselves and can be associated with a massive reduction in quality of life, including social isolation and wish to hasten death. Often there is an affective component such as anxiety or panic. Objective parameters do not necessarily correlate with the subjective experience. Health professionals often underestimate and inadequately treat the burden of dyspnea. The introduction of the concept of chronic breathlessness syndrome or acute-on-chronic-breathlessness aims to illustrate the nature of the condition and facilitate the identification and access to appropriate treatment. The management of dyspnea is complex, and for effective treatment, a combination of general, non-pharmacological, and pharmacological measures is usually advisable. Opioids should be offered to patients with incurable cancer and refractory dyspnea for symptom relief. They can be supplemented with benzodiazepines in cases of concomitant anxiety. The administration of oxygen is only indicated in cases of hypoxemia. Key measures include education, self-management skills acquisition and advance care planning for emergency situations.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 4","pages":"145-150"},"PeriodicalIF":0.2,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142074223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书